ArticleInternational journal of chronic obstructive pulmonary disease2026
Genetically Predicted Use of Common Analgesics and Risk of Chronic Obstructive Pulmonary Disease: A Bidirectional Mendelian Randomization Study.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Observational studies suggest a link between common analgesic use and chronic obstructive pulmonary disease (COPD), but causality is unclear. This study aimed to investigate the bidirectional causal relationship between the genetically predicted use of paracetamol, aspirin, and ibuprofen, and COPD risk using a two-sample Mendelian randomization (MR) approach. Methods: We performed a bidirectional MR study using summary statistics from large-scale genome-wide association studies (GWAS). Genetic instruments for paracetamol, aspirin, and ibuprofen use were from the UK Biobank (N=457,547). COPD summary statistics were from the FinnGen consortium (24,138 cases, 409,070 controls). The primary analysis used the inverse-variance weighted (IVW) method. We conducted extensive sensitivity analyses (MR-Egger, weighted median, weighted mode, MR-PRESSO) to assess pleiotropy and heterogeneity. Results: Genetically predicted paracetamol use was significantly associated with an increased risk of COPD (IVW OR: 6.00, 95% CI: 2.43-14.82, P < 0.001). Conversely, genetically predicted aspirin use was associated with a decreased risk of COPD (IVW OR: 0.19, 95% CI: 0.05-0.71, P = 0.014). Genetically predicted ibuprofen use showed no significant association with COPD risk (IVW OR: 0.47, 95% CI: 0.06-3.82, P = 0.483). In the reverse analysis, genetic liability to COPD was not causally associated with the use of any of the three analgesics (P > 0.05). Sensitivity analyses supported the robustness of these findings, showing no significant directional pleiotropy or heterogeneity for the primary results. Conclusion: This MR study provides genetic evidence supporting a causal relationship between paracetamol use and an increased risk of COPD, and between aspirin use and a decreased risk. These findings suggest that the choice of analgesic may have important implications for COPD risk, warranting further clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.